AU2001230193A1 - Transdermal therapeutic system for the administration of zaleplon - Google Patents

Transdermal therapeutic system for the administration of zaleplon

Info

Publication number
AU2001230193A1
AU2001230193A1 AU2001230193A AU3019301A AU2001230193A1 AU 2001230193 A1 AU2001230193 A1 AU 2001230193A1 AU 2001230193 A AU2001230193 A AU 2001230193A AU 3019301 A AU3019301 A AU 3019301A AU 2001230193 A1 AU2001230193 A1 AU 2001230193A1
Authority
AU
Australia
Prior art keywords
tts
zaleplon
therapeutic system
transdermal therapeutic
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230193A
Other languages
English (en)
Inventor
Thorsten Selzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of AU2001230193A1 publication Critical patent/AU2001230193A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001230193A 2000-02-01 2001-01-18 Transdermal therapeutic system for the administration of zaleplon Abandoned AU2001230193A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10004790A DE10004790B4 (de) 2000-02-01 2000-02-01 Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
DE10004790 2000-02-01
PCT/EP2001/000532 WO2001056576A1 (de) 2000-02-01 2001-01-18 Transdermales therapeutisches system zur verabreichung von zaleplon

Publications (1)

Publication Number Publication Date
AU2001230193A1 true AU2001230193A1 (en) 2001-08-14

Family

ID=7629739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230193A Abandoned AU2001230193A1 (en) 2000-02-01 2001-01-18 Transdermal therapeutic system for the administration of zaleplon

Country Status (10)

Country Link
US (1) US20030013726A1 (da)
EP (1) EP1251853B1 (da)
JP (1) JP2003525224A (da)
KR (1) KR100610624B1 (da)
AT (1) ATE252904T1 (da)
AU (1) AU2001230193A1 (da)
DE (2) DE10004790B4 (da)
DK (1) DK1251853T3 (da)
ES (1) ES2210122T3 (da)
WO (1) WO2001056576A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK472004A3 (en) 2001-08-01 2004-12-01 Biogal Gyogyszergyar Purification and crystalline forms of zaleplon
PL373694A1 (en) * 2002-02-15 2005-09-05 Teva Gyogyszergyar Reszvenytarsasag Powder composition comprising zaleplon of defined particle size distribution and pharmaceutical products made therefrom
CN100402036C (zh) * 2004-04-26 2008-07-16 袁重华 治疗失眠的涂敷剂
CN1306934C (zh) * 2004-09-29 2007-03-28 中国人民解放军军事医学科学院基础医学研究所 一种含有扎莱普隆的药物组合物及制备方法
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
CA2721493C (en) 2008-04-18 2017-11-28 Intec Pharma Ltd. Carbidopa/levodopa gastroretentive drug delivery
WO2010045615A2 (en) * 2008-10-16 2010-04-22 Cenomed Biosciences, Llc Treatment of organophosphate exposure with ocinaplon
PL2378883T3 (pl) * 2008-12-04 2016-06-30 Intec Pharma Ltd SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU
US9522595B2 (en) * 2011-01-27 2016-12-20 Irobot Defense Holdings, Inc. Small unmanned ground vehicle
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
DE19975048I2 (de) * 1985-05-13 2001-06-13 American Cyanamid Co 7-(3-Disubstituierte Amino)phenyl pyrazolo 1,5-a -pyrimidine
IE62871B1 (en) * 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration
CA2116036A1 (en) * 1991-10-18 1993-04-29 F. Eugene Yates Device for the transdermal administration of melatonin
DE19501022C1 (de) * 1995-01-14 1996-06-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung
JPH09136835A (ja) * 1995-11-14 1997-05-27 Sekisui Chem Co Ltd 経皮吸収貼付剤
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
JPH09278651A (ja) * 1996-04-05 1997-10-28 Sekisui Chem Co Ltd 経皮吸収貼付剤
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
JPH11228414A (ja) * 1998-02-06 1999-08-24 Sumitomo Pharmaceut Co Ltd タンドスピロン経皮剤
JP4275768B2 (ja) * 1998-06-18 2009-06-10 久光製薬株式会社 水性粘着膏体
US20030091632A1 (en) * 1999-08-26 2003-05-15 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto

Also Published As

Publication number Publication date
ATE252904T1 (de) 2003-11-15
EP1251853B1 (de) 2003-10-29
DE50100870D1 (de) 2003-12-04
WO2001056576A1 (de) 2001-08-09
KR20020079819A (ko) 2002-10-19
DK1251853T3 (da) 2004-02-16
DE10004790B4 (de) 2004-09-09
ES2210122T3 (es) 2004-07-01
DE10004790A1 (de) 2001-08-09
KR100610624B1 (ko) 2006-08-09
US20030013726A1 (en) 2003-01-16
EP1251853A1 (de) 2002-10-30
JP2003525224A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
UA84303C2 (ru) Система для трансдермальной доставки лечебного средства
AU7253501A (en) Transdermal therapeutic system for highly dispersed silicon dioxide
IE800059L (en) Polymeric diffusion matrix
AU533491B2 (en) Bandage for administering drugs to the skin
AU676623B2 (en) Non-occlusive adhesive patch for applying medication to the skin
PH31473A (en) Transdermal therapeutic system comprising galanthamine as active component.
AU2001230193A1 (en) Transdermal therapeutic system for the administration of zaleplon
DE69923348D1 (de) Transdermales arzneistoffverabreichungssystem
IL106512A (en) Plaster for the transdermal application of steroid hormones and process for the preparation thereof
MXPA02009103A (es) Sistema terapeutico transdermal para la administracion de lerisetron.
WO1994025025A3 (de) Systeme zur kontrollierten abgabe von pilocarpin
PT1011674E (pt) Sistema terapeutico transdermico com a substancia activa escopolamina base
NO952908D0 (no) Nitroglycerolholdig plaster, fremgangsmåte for fremstilling, samt anvendelse av plasteret
YU71293A (sh) Transdermalni terapijski sistem za davanje fizostigmina na koži i postupak za njegovu izradu
TW273516B (en) Adhesive matrix-type transdermal therapeutic set for motion sickness